Asessment of Serum Procalcitonin Level in Patients with Chronic Obstructive Pulmonary Disease

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is currently one of the leading causes of mortality in the globe, according to the World Health Organization. When COPD sufferers have an acute exacerbation, the infectiondetecting hormone procalcitonin (PCT) may be administered (AECOPD). The development of COPD is linked to PCT and other viral inflammatory variables. The goal of this research was to determine the PCT level in patients with COPD. Methods: ELISA was used to monitor PCT levels throughout AECOPD and after the patient was stabilised. Study groups differed significantly in PCT results (P-value 0.001). Stable (2220.9 pg/ml) and exacerbation (2679 pg/ml) groups had higher levels, whereas the control group had considerably lower levels (1696.9 pg/ml). Compared to the control group (2220.9 pg/ml), it was considerably greater in the exacerbation group (2679 pg/ml). Conclusion: In patients with stable COPD and AECOPD, PCT has a negative relationship with severity.

Evaluation of Salivary Biomarkers and Spirometry for Diagnosing COPD in Non-Smokers and Smokers of Polish Origin

“…In healthy individuals, the levels of PCT are below 0.01 g/L but can increase up to 100 g/L during severe infections and had a half-life of 25–30 h in blood serum [ 53 , 54 ]. In a study analyzing the relation of PCT with acute exacerbation of COPD, the control group of healthy individuals showed lower PCT levels in serum than the stable and exacerbated COPD patients [ 55 ]. The salivary PCT levels were found to be higher in the smoker group compared to the non-smokers and COPD patients.…”